



**Anti-Thyroid Peroxidase (Anti-TPO)  
Test System  
Product Code: 1125-300**

### 1.0 INTRODUCTION

**Intended Use: The Quantitative Determination of Thyroid Peroxidase (TPO) Autoantibodies in Human Serum or Plasma by a Microplate Enzyme Immunoassay, Colorimetric. Measurements of TPO autoantibodies may aid in the diagnosis of certain thyroid diseases such as Hashimoto's and Grave's as well as nontoxic goiter.**

### 2.0 SUMMARY AND EXPLANATION OF THE TEST

Antibodies to thyroid peroxidase have been shown to be characteristically present from patients with Hashimoto thyroiditis (95%), idiopathic myxedema (90%) and Graves Disease (80%)<sup>1</sup>. In fact 72% of patients positive for anti-TPO exhibit some degree of thyroid dysfunction.<sup>2</sup> This has led to the clinical measurement becoming a valuable tool in the diagnosis of thyroid dysfunction.

Measurements of antibodies to TPO have been done in the past by Passive Hemagglutination (PHA). PHA tests do not have the sensitivity of enzyme immunoassay and are limited by subjective interpretation. This procedure, with the enhanced sensitivity of EIA, permits the detectability of subclinical levels of antibodies to TPO. In addition, the results are quantitated by a spectrophotometer, which eliminates subjective interpretation.

Monobind's microplate enzyme immunoassay methodology provides the technician with optimum sensitivity while requiring few technical manipulations. In this method, serum reference, diluted patient specimen, or control is first added to a microplate well. Biotinylated Thyroid Peroxidase Antigen (TPO) is added, and then the reactants are mixed. Reaction results between the autoantibodies to TPO and the biotinylated TPO to form an immune complex, which is deposited to the surface of streptavidin coated wells through the high affinity reaction of biotin and streptavidin.

After the completion of the required incubation period, aspiration or decantation separates the reactants that are not attached to the wells. An enzyme anti-human IgG conjugate is then added to permit quantitation of reaction through interacting with human IgG of the immune complex. After washing, the enzyme activity is determined by reaction with substrate to produce color.

The employment of several serum references of known antibody activity permits construction of a graph of enzyme and antibody activities. From comparison to the dose response curve, an unknown specimen's enzyme activity can be correlated with autoimmune antibody level.


### 3.0 PRINCIPLE

#### A Sequential ELISA Method (TYPE 1)

The reagents required for the sequential ELISA assay include immobilized antigen, circulating autoantibody and enzyme-linked


species-specific antibody. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated thyroid peroxidase antigen.

Upon mixing the biotinylated antigen and a serum containing the autoantibody, a reaction results between the antigen and the antibody to form an immune-complex. The interaction is illustrated by the following equation:



$\text{B}^{\text{in}}\text{Ag}_{(\text{TPO})}$  = Biotinylated Antigen (Constant Quantity)  
 $h\text{-Ab}_{(x\text{-TPO})}$  = Human Auto-Antibody (Variable Quantity)  
 $\text{Ab}_{(x\text{-TPO})} - \text{B}^{\text{in}}\text{Ag}_{(\text{TPO})}$  = Immune Complex (Variable Quantity)  
 $k_a$  = Rate Constant of Association  
 $k_{-a}$  = Rate Constant of Disassociation

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antigen. This interaction is illustrated below:



After the incubation time, the well is washed to separate the unbound components by aspiration and/or decantation. The enzyme linked species-specific antibody (anti-h-IgG) is then added to the microwells. This conjugates binds to the immune complex that formed.

$\text{I.C.}_{(h\text{-IgG})} + \text{EnzAb}_{(x\text{-h-IgG})} \Rightarrow \text{EnzAb}_{(x\text{-h-IgG})} - \text{I.C.}_{(h\text{-IgG})}$   
 $\text{I.C.}_{(h\text{-IgG})}$  = Immobilized Immune complex (Variable Quantity)  
 $\text{EnzAb}_{(x\text{-h-IgG})}$  = Enzyme-antibody Conjugate (Constant Quantity)  
 $\text{EnzAb}_{(x\text{-h-IgG})} - \text{I.C.}_{(h\text{-IgG})}$  = Ag-Ab Complex (Variable Quantity)

The anti-h-IgG enzyme conjugate that binds to the immune complex in a second incubation is separated from unreacted material by a wash step. The enzyme activity in this fraction is directly proportional to the antibody concentration in the specimen. By utilizing several different serum references of known antibody activity, a reference curve can be generated from which the antibody activity of an unknown can be ascertained

### 4.0 REAGENTS

#### Materials Provided

##### A. Anti-TPO Calibrators – 1ml/vial Icons A-F

Six (6) vials of references for anti-TPO at levels of 0(A), 25(B), 50(C), 100(D), 250(E) and 500(F) IU/ml. Store at 2-8°C. A preservative has been added.

**Note:** The calibrators, human serum based, were calibrated using a reference preparation, which was assayed against the Medical Research Council (MRC) International Standard 66/387 for anti thyroid microsome.

##### B. TPO Biotin Reagent – 13ml/vial – Icon ▽

One (1) vial of biotinylated thyroid peroxidase antigen stabilized in a buffering matrix. A preservative has been added. Store at 2-8°C

##### C. Anti-TPO Enzyme Reagent – 13ml/vial – Icon ⊕

One (1) vial of anti-human IgG-horseradish peroxidase (HRP) conjugate stabilized in a buffered matrix. A preservative has been added. Store at 2-8°C

##### D. Streptavidin Coated Plate – 96 wells – Icon ↓

One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

##### E. Serum Diluent – 20ml/vial

One (1) vial of serum diluent concentrate that containing buffer salts and a dye. Store at 2-8°C.

##### F. Wash Solution Concentrate – 20ml/vial – Icon ⬇️

One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

##### G. Substrate A – 7ml/vial – Icon S<sup>A</sup>

One (1) vial containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C. See "Reagent Preparation."

##### H. Substrate B – 7ml/vial – Icon S<sup>B</sup>

One (1) vial containing hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in buffer. Store at 2-8°C. See "Reagent Preparation."

##### I. Stop Solution – 8ml/vial – Icon ⊖

One (1) vial containing a strong acid (1N HCl). Store at 2-8°C.

### J. Product Instructions.

**Note 1:** Do not use reagents beyond the kit expiration date.

**Note 2:** Opened reagents are stable for sixty (60) days when stored at 2-8°C. **Kit and component stability are identified on the label.**

**Note 3:** Above reagents are for a single 96-well microplate.

#### Required But Not Provided:

- Pipette capable of delivering 0.010ml (10µl), 0.025ml (25µl), and 0.050ml (50µl) volumes with a precision of better than 1.5%.
- Dispenser(s) for repetitive deliveries of 0.100 & 0.350ml (100 & 350µl) volumes with a precision of better than 1.5%.
- Microplate washers or a squeeze bottle (optional).
- Microplate Reader with 450nm and 620nm wavelength absorbance capability.
- Absorbent Paper for blotting the microplate wells.
- Plastic wrap or microplate cover for incubation steps.
- Vacuum aspirator (optional) for wash steps.
- Test tube(s) for patient dilution.
- Timer.
- Quality control materials.

### 5.0 PRECAUTIONS

**For In Vitro Diagnostic Use  
Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe Disposal of kit components must be according to local regulatory and statutory requirement.**

### 6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood; serum or plasma in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants (for serum) or evacuated tube(s) containing EDTA or heparin. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

**In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.**

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.05ml (50µl) of the specimen is required.

### 7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the normal, borderline and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

### 8.0 REAGENT PREPARATION

- Serum Diluent**  
Dilute the serum diluent to 200ml in a suitable container with distilled or deionized water. Store at 2-8°C.
- Wash Buffer**  
Dilute contents of wash concentrate to 1000 ml with distilled or deionized water in a suitable storage container. Diluted buffer can be stored at 2-30°C for up to 60 days.
- Working Substrate Solution** – Stable for one (1) year.  
Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B'. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8°C.
- Patient Sample Dilution (1/100)**  
Dispense 0.010ml (10µl) of each patient specimen into 1ml (1000µl) of serum diluent. Cover and vortex or mix thoroughly by inversion. Store at 2-8°C for up to forty-eight (48) hours.

**Note 1 : Do not use the working substrate if it looks blue.  
Note 2: Do not use reagents that are contaminated or have bacteria growth.**

### 9.0 TEST PROCEDURE

*Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C).  
\*\*\*Test Procedure should be performed by a skilled individual or trained professional\*\*\**

- Format the microplates' wells for each serum reference calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- Pipette 0.025 ml (25µl) of the appropriate serum reference calibrator, control or diluted patient specimen into the assigned well.
- Add 0.100 ml (100µl) of the TPO Biotin Reagent
- Swirl the microplate gently for 20-30 seconds to mix and cover.
- Incubate 60 minutes at room temperature.
- Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
- Add 350µl of wash buffer (see Reagent Preparation Section), decant (blot and tap) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- Add 0.100 ml (100µl) of the x-TPO Enzyme Reagent to all wells. **Always add reagents in the same order to minimize reaction time differences between wells.**  
**DO NOT SHAKE THE PLATE AFTER ENZYME ADDITION**
- Incubate for thirty (30) minutes at room temperature.
- Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
- Add 350µl of wash buffer (see Reagent Preparation Section), decant (blot and tap) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**  
**DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
- Incubate at room temperature for fifteen (15) minutes.
- Add 0.050ml (50µl) of stop solution to each well and mix gently for 15-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells.**
- Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. **The results should be read within thirty (30) minutes of adding the stop solution.**

**Note:** For re-assaying specimens with concentrations greater than 500 IU/ml, dilute the sample an additional 1:5 or 1:10 using the original diluted material. Multiply by the dilution factor to obtain the concentration of the specimen.

## 10.0 CALCULATION OF RESULTS

A reference curve is used to ascertain the concentration of anti-TPO in unknown specimens.

1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate serum reference versus the corresponding anti-TPO activity in IU/ml on linear graph paper.
3. Draw the best-fit curve through the plotted points.
4. To determine the level of anti-TPO activity for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in IU/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.323) intersects the dose response curve at 200 IU/ml anti-TPO concentration (See Figure 1).


**Note:** Computer data reduction software designed for ELISA assays may also be used for the data reduction. If such software is utilized, the validation of the software should be ascertained.

EXAMPLE 1

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (IU/ml)
Cal A	A1	0.022	0.026	0
	B1	0.030		
Cal B	C1	0.240	0.244	25
	D1	0.247		
Cal C	E1	0.437	0.430	50
	F1	0.422		
Cal D	G1	0.795	0.788	100
	H1	0.782		
Cal E	A2	1.610	1.590	250
	B2	1.572		
Cal F	C2	2.659	2.600	500
	D2	2.533		
Patient	E2	1.294	1.323	200
	F2	1.351		

\*The data presented in Example 1 and Figure 1 are for illustration only and **should not** be used in lieu of a standard curve prepared with each assay.

Figure 1



## 11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator F should be  $\geq 1.3$ .
2. Four out of six quality control pools should be within the established ranges.

## 12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

## 12.1 Assay Performance

1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Very high concentration of anti-TPO in patient specimens can contaminate samples immediately following these extreme levels. Bad duplicates are indicative of cross contamination. Repeat any sample, which follows any patient specimen with over 3.0 units of absorbance.
10. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
11. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
12. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
13. Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from [Monobind@monobind.com](mailto:Monobind@monobind.com).

## 12.2 Interpretation

1. **Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988;34:27-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.
4. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
5. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
6. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations. The presence of autoantibodies to TPO is confirmed when the serum level exceeds 40 IU/ml. The clinical significance of the result, coupled with anti-thyroglobulin activity, should be used in evaluating the thyroid condition. However, clinical inferences should not be solely based on this test but rather as an adjunct to the clinical manifestations of the patient and other relevant tests.

## 13.0 EXPECTED RANGES OF VALUES

A study of normal population was undertaken to determine expected values for the anti-TPO AccuBind® ELISA test system. The number (n), mean (x) and standard deviation ( $\sigma$ ) are given in Table 1. Values in excess of 40 IU/ml are considered positive for the presence of anti-TPO autoantibodies.

TABLE 1  
Expected Values for the Anti-TPO ELISA Test System (In IU/ml)

Number	100
Mean	17.6
Standard deviation	10.8
Upper 95% (+2 $\sigma$ ) level	39.2

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal"-persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

## 14.0 PERFORMANCE CHARACTERISTICS

### 14.1 Precision

The within and between assay precisions of the anti-TPO AccuBind® ELISA test system were determined by analyses on three different levels of pool control sera. The number (N), mean value (X), standard deviation ( $\sigma$ ) and coefficient of variation (C.V) for each of these control sera are presented in Tables 2 and 3.

TABLE 2  
Within Assay Precision (Values in IU/ml)

Sample	N	X	$\sigma$	C.V.
Pool 1	20	25.5	1.5	5.7%
Pool 2	20	120.5	4.6	3.8%
Pool 3	20	352.4	14.8	4.2%

TABLE 3\*  
Between Assay Precision (Values in IU/ml)

Sample	N	X	$\sigma$	C.V.
Pool 1	10	26.5	1.8	6.8%
Pool 2	10	118.5	5.3	4.5%
Pool 3	10	365.4	22.5	6.2%

\*As measured in ten experiments in duplicate.

### 14.2 Sensitivity

The anti-TPO AccuBind® ELISA test system has a sensitivity of 0.92 IU/ml. The sensitivity (detection limit) was ascertained by determining the variability of the '0 IU/ml' calibrator and using the 2 $\sigma$  (95% certainty) statistic to calculate the minimum dose.

### 14.3 Accuracy

The anti-TPO AccuBind® ELISA test system was compared with a reference anti-TPO ELISA microplate. Biological specimens from normal and disease states populations were used. The disease states included: Hashimoto's thyroiditis, Graves Disease, thyroid nodules as well as thyroid carcinoma. The total number of such specimens was 82. The least square regression equation and the correlation coefficient were computed for the anti-TPO AccuBind® ELISA test system in comparison with the reference method. The data obtained is displayed in Table 4.

TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
Monobind	122.9	$y = 1.02(x) - 5.1$	0.989
Reference	127.0		

### 14.4 Specificity

Interferences from ANA, DNA, thyroglobulin (TPO) and rheumatoid antibodies were found to be insignificant

## 15.0 REFERENCES

1. Volpé R, "Autoimmune disease of the endocrine system", Boca Raton FL, CRC Press (1990).
2. Volpé R, *Clin Chem*, 40, 2132 (1994).
3. Beever K, et al, *Clin Chem*, 35, 1949-54 (1989).
4. Mak T, *Clin Chem*, 40, 2128 (1994).
5. Czarnocka B, Ruff J, Ferrand M, Carayon P, Lissitzky S, "Purification of the human thyroid and its identification as the microsomal antigen involved in the human thyroid disease", *FEBS Letts*, 190, 147-52 (1985).

6. Portman L, hamada N, Heinrich G, Degroot LJ, "Anti-Thyroid Peroxidase antibody in patients with autoimmune thyroid disease; Possible identity with anti-microsomal antibody", *J of Clin Endocrinology & Metabolism*, 61,1001-3 (1985).
7. Chiavato L, Pinchera A, "The microsomal-peroxidase antigen: modulation of its expression in thyroid cells", *Autoimmunity*, 10, 319-31 (1991).
8. Nunez J, Pommier J, "Formation of thyroid hormones", *Vitam Horm*, 39, 175-229 (1982).
9. Ekholm R, "Biosynthesis of thyroid hormones", *Int Rev Cytol*, 120, 243-288 (1990).
10. Degroot LJ, "Heterogeneity of human antibodies to TPO Thyroperoxidase", *Thyroid Autoimmunity*, 207,177-182 (1990).

Revision: 4 Date: 2019-JUL-16 DCO: 1353  
MP1125 Product Code: 1125-300

Size	96(A)
A)	1ml set
B)	1 (13ml)
C)	1 (13ml)
D)	1 plate
E)	1 (20ml)
F)	1 (20ml)
G)	1 (7ml)
H)	1 (7ml)
I)	1(8ml)

For Orders and Inquires, please contact


**Monobind Inc.**  
100 North Pointe Drive  
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Mail: [info@monobind.com](mailto:info@monobind.com)  
Fax: +1 949.951.3539 Fax: [www.monobind.com](http://www.monobind.com)



Please visit our website to learn more about our products and services.

## Glossary of Symbols (EN 980/ISO 15223)



EC REP  
Authorized Rep in European Country

CE  
European Conformity